Raphael Pharmaceutical (RAPH) Non Operating Income (2020 - 2024)
Raphael Pharmaceutical (RAPH) reported Non Operating Income of -$1000.0 for Q4 2024, up 91.67% on a YoY basis from -$521.74 in Q1 2024, and up 85.71% sequentially from -$7000.0 in Q3 2024.
Raphael Pharmaceutical (RAPH) Non Operating Income (2020 - 2024) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 5 years of Non Operating Income data on file, last reported at -$1000.0 in Q4 2024.
- For the quarter ending Q4 2024, Non Operating Income rose 91.67% year-over-year to -$1000.0; the trailing twelve-month figure through Dec 2024 stood at -$10000.0 (up 16.67% YoY), and the FY2025 full-year result was -$34000.0, down 240.0% from the prior year.
- Non Operating Income rose to -$1000.0 in Q4 2024, from -$7000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $7000.0 in Q4 2021 to a low of -$17000.0 in Q3 2022.
- A 5-year average of -$3647.1 and a median of -$3000.0 in 2020 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income jumped 333.33% in 2021 and tumbled 1300.0% in 2023, its largest moves.
- Tracing RAPH's Non Operating Income over 5 years: stood at -$3000.0 in 2020, then jumped by 333.33% to $7000.0 in 2021, then slumped by 85.71% to $1000.0 in 2022, then plunged by 1300.0% to -$12000.0 in 2023, then surged by 91.67% to -$1000.0 in 2024.
- Business Quant data shows RAPH's Non Operating Income at -$1000.0 in Q4 2024, -$7000.0 in Q3 2024, and $1000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -7.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | -3,000.00 |
| Dec 31, 2023 | -12,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | -6,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -17,000.00 |
| Jun 30, 2022 | -15,000.00 |
| Mar 31, 2022 | -10,000.00 |
| Dec 31, 2021 | 7,000.00 |
| Sep 30, 2021 | 2,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Mar 31, 2021 | -3,000.00 |
| Dec 31, 2020 | -3,000.00 |